Vertex Pharmaceuticals Incorporated is a biotechnology company. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI and KALYDECO. It offers its products to treat people with CF who have specific mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. Its CFTR correctors, such as lumacaftor, tezacaftor, and elexacaftor, help CFTR proteins reach the cell surface. It offers pipeline of small molecule medicines in other serious diseases where it has insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases.
52 Week high
52 Week low
The Motley Fool • 1 day ago • VRTX2 Healthcare Stocks That Could Make You Richer
The Motley Fool • 2 days ago • VRTX3 Unstoppable Stocks to Buy and Hold for the Next 20 Years
Zacks Investment Research • 5 days ago • VRTXVertex (VRTX) Gets Positive CHMP Opinion for Kaftrio Expanded Use
Business Wire • 9 days ago • VRTXVertex Researchers Awarded 2024 Breakthrough Prize in Life Sciences
Charts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.